Diversified Consumer Services
Company Overview of University of Minnesota
University of Minnesota is an educational institution that provides undergraduate and graduate programs. It offers courses in business administration, agriculture and life sciences, arts, medicine, engineering, mathematics, nursing and health sciences, and social services. University of Minnesota was founded in 1851 and is based in Minneapolis, Minnesota.
3 Morrill Hall
100 Church Street S.E.
Minneapolis, MN 55455
Founded in 1851
Key Executives for University of Minnesota
President and Board of Regents
Vice President of Research
Vice President of Health Sciences and Dean of Medical School
Vice President for University Relations
Compensation as of Fiscal Year 2015.
University of Minnesota Key Developments
University of Minnesota Presents at Alliance for Regenerative Medicine Stem Cell Meeting on the Mesa, Oct-09-2015 03:00 PM
Oct 2 15
University of Minnesota Presents at Alliance for Regenerative Medicine Stem Cell Meeting on the Mesa, Oct-09-2015 03:00 PM. Venue: Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 92037, United States. Speakers: Joseph Metzger, Professor & Chair, Department of Integrative Biology & Physiology.
Calyxt Signs Licensing Agreement with University of Minnesota
Jul 29 15
Calyxt Inc. has signed an exclusive licensing agreement with The University of Minnesota to grant Cellectis the worldwide rights to use the technology covered by the patent rights of the family PCT/US2013/046495 entitled Gene Targeting Using Replicating DNA Molecules. Both the partners are based in the US.
Fate Therapeutics Enters into Research Collaboration with University of Minnesota on Development of Natural Killer Cell-Based Immuno-Oncology Candidates
Jul 16 15
Fate Therapeutics entered into a research collaboration with the University of Minnesota focused on the development of natural killer (NK) cell-based immuno-oncology candidates. Fate Therapeutics will leverage the University's pioneering work on NK cell-based therapies, as well as its own cell-programming and stem-cell technology platform to develop 'off-the-shelf' candidates with anti-tumour activity. The collaboration will focus on two main therapeutic projects, one related to optimisation of 'adaptive' NK cells, and the other focused on utilisation of induced pluripotent stem cells (iPSCs) to derive NK cell-based candidates. Based on the terms of the agreement, Fate Therapeutics has the option to obtain exclusive patent rights to candidates resulting from the collaboration.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries